- Home
- CBRE vs TOVX Comparison
CBRE vs TOVX Comparison
Compare CBRE & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBRE
- TOVX
- Stock Information
- Founded
- CBRE 1906
- TOVX 2001
- Country
- CBRE United States
- TOVX United States
- Employees
- CBRE N/A
- TOVX N/A
- Industry
- CBRE Real Estate
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- CBRE Finance
- TOVX Health Care
- Exchange
- CBRE Nasdaq
- TOVX Nasdaq
- Market Cap
- CBRE 40.1B
- TOVX 3.5M
- IPO Year
- CBRE 2004
- TOVX 2006
- Fundamental
- Price
- CBRE $129.30
- TOVX $1.14
- Analyst Decision
- CBRE Buy
- TOVX Strong Buy
- Analyst Count
- CBRE 9
- TOVX 1
- Target Price
- CBRE $133.33
- TOVX $6.00
- AVG Volume (30 Days)
- CBRE 2.1M
- TOVX 96.3K
- Earning Date
- CBRE 02-13-2025
- TOVX 11-12-2024
- Dividend Yield
- CBRE N/A
- TOVX N/A
- EPS Growth
- CBRE 66.15
- TOVX N/A
- EPS
- CBRE 3.10
- TOVX N/A
- Revenue
- CBRE $34,313,000,000.00
- TOVX N/A
- Revenue This Year
- CBRE $13.52
- TOVX N/A
- Revenue Next Year
- CBRE $11.01
- TOVX N/A
- P/E Ratio
- CBRE $41.62
- TOVX N/A
- Revenue Growth
- CBRE 10.00
- TOVX N/A
- 52 Week Low
- CBRE $82.75
- TOVX $1.14
- 52 Week High
- CBRE $142.00
- TOVX $17.00
- Technical
- Relative Strength Index (RSI)
- CBRE 41.60
- TOVX 36.15
- Support Level
- CBRE $125.38
- TOVX $1.23
- Resistance Level
- CBRE $140.70
- TOVX $1.21
- Average True Range (ATR)
- CBRE 3.43
- TOVX 0.07
- MACD
- CBRE -1.51
- TOVX 0.01
- Stochastic Oscillator
- CBRE 25.59
- TOVX 0.00
About CBRE CBRE Group Inc
CBRE Group provides a wide range of real estate services to owners, occupants, and investors worldwide, including leasing, property and project management, and capital markets advisory. CBRE's investment management arm manages over $140 billion for clients across diverse public and private real estate strategies.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.